183 related articles for article (PubMed ID: 24112036)
1. Neuroprotective and anti-apoptotic effects of liraglutide on SH-SY5Y cells exposed to methylglyoxal stress.
Sharma MK; Jalewa J; Hölscher C
J Neurochem; 2014 Feb; 128(3):459-71. PubMed ID: 24112036
[TBL] [Abstract][Full Text] [Related]
2. Liraglutide can reverse memory impairment, synaptic loss and reduce plaque load in aged APP/PS1 mice, a model of Alzheimer's disease.
McClean PL; Hölscher C
Neuropharmacology; 2014 Jan; 76 Pt A():57-67. PubMed ID: 23973293
[TBL] [Abstract][Full Text] [Related]
3. The protective effects of liraglutide on AD-like neurodegeneration induced by oxidative stress in human neuroblastoma SH-SY5Y cells.
Zheng C; Zhou M; Sun J; Xiong H; Peng P; Gu Z; Deng Y
Chem Biol Interact; 2019 Sep; 310():108688. PubMed ID: 31173752
[TBL] [Abstract][Full Text] [Related]
4. Liraglutide prevents beta-amyloid-induced neurotoxicity in SH-SY5Y cells via a PI3K-dependent signaling pathway.
Liu XY; Wang LX; Chen Z; Liu LB
Neurol Res; 2016 Apr; 38(4):313-9. PubMed ID: 27108910
[TBL] [Abstract][Full Text] [Related]
5. Novel incretin analogues improve autophagy and protect from mitochondrial stress induced by rotenone in SH-SY5Y cells.
Jalewa J; Sharma MK; Hölscher C
J Neurochem; 2016 Oct; 139(1):55-67. PubMed ID: 27412483
[TBL] [Abstract][Full Text] [Related]
6. The human glucagon-like peptide-1 analogue liraglutide regulates pancreatic beta-cell proliferation and apoptosis via an AMPK/mTOR/P70S6K signaling pathway.
Miao XY; Gu ZY; Liu P; Hu Y; Li L; Gong YP; Shu H; Liu Y; Li CL
Peptides; 2013 Jan; 39():71-9. PubMed ID: 23116613
[TBL] [Abstract][Full Text] [Related]
7. Enhancing the GLP-1 receptor signaling pathway leads to proliferation and neuroprotection in human neuroblastoma cells.
Li Y; Tweedie D; Mattson MP; Holloway HW; Greig NH
J Neurochem; 2010 Jun; 113(6):1621-31. PubMed ID: 20374430
[TBL] [Abstract][Full Text] [Related]
8. Lixisenatide, a drug developed to treat type 2 diabetes, shows neuroprotective effects in a mouse model of Alzheimer's disease.
McClean PL; Hölscher C
Neuropharmacology; 2014 Nov; 86():241-58. PubMed ID: 25107586
[TBL] [Abstract][Full Text] [Related]
9. Mutated recombinant human glucagon-like peptide-1 protects SH-SY5Y cells from apoptosis induced by amyloid-beta peptide (1-42).
Qin Z; Sun Z; Huang J; Hu Y; Wu Z; Mei B
Neurosci Lett; 2008 Oct; 444(3):217-21. PubMed ID: 18760331
[TBL] [Abstract][Full Text] [Related]
10. Liraglutide, a human glucagon-like peptide-1 analogue, stimulates AKT-dependent survival signalling and inhibits pancreatic β-cell apoptosis.
Kapodistria K; Tsilibary EP; Kotsopoulou E; Moustardas P; Kitsiou P
J Cell Mol Med; 2018 Jun; 22(6):2970-2980. PubMed ID: 29524296
[TBL] [Abstract][Full Text] [Related]
11. Liraglutide is neurotrophic and neuroprotective in neuronal cultures and mitigates mild traumatic brain injury in mice.
Li Y; Bader M; Tamargo I; Rubovitch V; Tweedie D; Pick CG; Greig NH
J Neurochem; 2015 Dec; 135(6):1203-1217. PubMed ID: 25982185
[TBL] [Abstract][Full Text] [Related]
12. ERK- and Akt-dependent neuroprotection by erythropoietin (EPO) against glyoxal-AGEs via modulation of Bcl-xL, Bax, and BAD.
Shen J; Wu Y; Xu JY; Zhang J; Sinclair SH; Yanoff M; Xu G; Li W; Xu GT
Invest Ophthalmol Vis Sci; 2010 Jan; 51(1):35-46. PubMed ID: 19628748
[TBL] [Abstract][Full Text] [Related]
13. Glucagon-like Peptide-1 Analogues Inhibit Proliferation and Increase Apoptosis of Human Prostate Cancer Cells in vitro.
Li XN; Bu HM; Ma XH; Lu S; Zhao S; Cui YL; Sun J
Exp Clin Endocrinol Diabetes; 2017 Feb; 125(2):91-97. PubMed ID: 28008585
[No Abstract] [Full Text] [Related]
14. Diabetes as a risk factor for Alzheimer's disease: insulin signalling impairment in the brain as an alternative model of Alzheimer's disease.
Hölscher C
Biochem Soc Trans; 2011 Aug; 39(4):891-7. PubMed ID: 21787319
[TBL] [Abstract][Full Text] [Related]
15. Liraglutide improves hippocampal synaptic plasticity associated with increased expression of Mash1 in ob/ob mice.
Porter WD; Flatt PR; Hölscher C; Gault VA
Int J Obes (Lond); 2013 May; 37(5):678-84. PubMed ID: 22665137
[TBL] [Abstract][Full Text] [Related]
16. The peptide-hormone glucagon-like peptide-1 activates cAMP and inhibits growth of breast cancer cells.
Ligumsky H; Wolf I; Israeli S; Haimsohn M; Ferber S; Karasik A; Kaufman B; Rubinek T
Breast Cancer Res Treat; 2012 Apr; 132(2):449-61. PubMed ID: 21638053
[TBL] [Abstract][Full Text] [Related]
17. Glucagon-like peptide-1 analogues enhance synaptic plasticity in the brain: a link between diabetes and Alzheimer's disease.
McClean PL; Gault VA; Harriott P; Hölscher C
Eur J Pharmacol; 2010 Mar; 630(1-3):158-62. PubMed ID: 20035739
[TBL] [Abstract][Full Text] [Related]
18. The role of GLP-1/GIP receptor agonists in Alzheimer's disease.
Yu CJ; Ma D; Song LL; Zhai ZN; Tao Y; Zhang Y; Cai LY; Hou YH; Chen HY; Wang L
Adv Clin Exp Med; 2020 Jun; 29(6):661-668. PubMed ID: 32614526
[TBL] [Abstract][Full Text] [Related]
19. Gamma-hydroxybutyrate, acting through an anti-apoptotic mechanism, protects native and amyloid-precursor-protein-transfected neuroblastoma cells against oxidative stress-induced death.
Wendt G; Kemmel V; Patte-Mensah C; Uring-Lambert B; Eckert A; Schmitt MJ; Mensah-Nyagan AG
Neuroscience; 2014 Mar; 263():203-15. PubMed ID: 24456637
[TBL] [Abstract][Full Text] [Related]
20. Epidermal growth factor receptor transactivation is necessary for glucagon-like peptide-1 to protect PC12 cells from apoptosis.
Kimura R; Okouchi M; Kato T; Imaeda K; Okayama N; Asai K; Joh T
Neuroendocrinology; 2013; 97(4):300-8. PubMed ID: 23147408
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
